natgillin/translations-raw huggingface dataset:
R1a is alkyl which may be substituted by A, cycloalkyl which may be substituted by A, alkenyl which may be substituted by A, alkynyl which may be substituted by A, aryl or a heterocyclic group, and is alkyl, 
a je alkil koji može biti supstituiran sa A, cikloalkil koji može biti supstituiran sa A, alkenil koji može biti supstituiran sa A, alkinil koji može biti supstituiran sa A, arilom ili heterocikličkom skupinom, a R7 je alkil, i spoj predstavljen formulom (V):
Typically, cilastatin is in the form of an amorphous sodium salt, but all salt forms and/or hydrated forms are included within the meaning of the term. 
Kombinacija sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačena time, da je inhibitor B-laktamaze u obliku natrijeve soli.
In this regard, an effective amount of hyaluronic acid may range from 0.1 to 5% by weight, preferably from 1 to 3% by weight, relative to the total weight of said solution comprising the hyaluronic acid or a salt thereof. 
Postupak prema patentnom zahtjevu 1, naznačen time što se umrežena hijaluronska kiselina iz koraka a) prethodno dobiva iz umrežavanja ne-umrežene hijaluronske kiseline s učinkovitom količinom najmanje jednog sredstva za umrežavanje koje se bira iz skupine koja sadrži 1,4-butandiol diglicidil eter.
A pharmaceutical composition according to claim 6 in a suitable form for the topical administration. 
Farmaceutski pripravak prema patentnom zahtjevu 10, naznačen time da je u pogodnom obliku za topičko davanje.
at least one pharmaceutically acceptable carrier, diluent, vehicle or excipient. Use of a therapeutically effective amount of a salt according to claim 1 for manufacturing a medicament for treating a disease which responds to an inhibition of protein kinase activity. 
Uporaba terapeutski učinkovite količine soli prema zahtjevu 1, naznačena time, da je za proizvodnju lijeka za liječenje bolesti koja odgovara inhibiciji djelovanja proteinske kinaze.
Process according to claim 1, wherein said mixture comprises an amount from about 78% to about 98% by weight of said fiber-reinforced polymeric material, the remaining amount by weight including said liquid adhesive. 
Postupak prema zahtjevu 1, naznačen time da navedena smjesa sadrži količinu od oko 78% do oko 98% težinski navedenog vlaknima ojačanog polimernog materijala, te preostala težinska količina uključujuće navedeno tekuće ljepilo.
providing a boron "ate" complex of formula (II): where 
Postupak za pripremu spoja estera organoborne kiseline formule (7):
-R' represents a hydrogen atom or an alkyl chain; 
-R' predstavlja vodikov atom ili alkilni lanac; qje0ili 1;
The compound according to any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof, wherein R4 represents H or a methyl group, The compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt thereof, wherein R5 and R6 are taken together with the nitrogen to which they are attached to form an azetidine ring, a pyrrolidine ring, a piperidine ring or a piperazine ring, wherein the azetidine ring, the pyrrolidine ring, the piperidine ring and the piperazine ring are optionally substituted with a tetrahydropyranyl group, a morpholinyl group or a 2,6-dimethylmorpholinyl group. 
Spoj prema bilo kojem od patentnih zahtjeva 1 do 5 ili njegova farmaceutski prihvatljiva sol, gdje R* predstavlja H ili metil grupu, Spoj prema bilo kojem od patentnih zahtjeva 1 do 6 ili njegova farmaceutski prihvatljiva sol, gdje R? i R* su uzeti zajedno sa dušikom za koji su vezani da formiraju azetidin prsten, pirolidin prsten, piperidin prsten ili piperazin prsten, gdje azetidin prsten, pirolidin prsten, piperidin prsten i piperazin prsten su po izboru supstituirani sa tetrahidropiranil grupom, morfolinil grupom ili 2,6-dimetilmorfolinil grupom.
At the end of this time sodium hydride (6 mg, 0.15 mmol, 60% dispersion in oil) and propyl bromide were added. 
Po isteku navedenog vremena dodaju se natrij hidrid (6 mg, 0.15 mmol, 60%-tna disperzija u ulju) i propil bromid.
The process of claim 7 or 8, wherein the dissolution of cholesterol, or derivatives thereof, in a CF is carried out in a reactor at an approximate pressure of 1 to 30 MPa and an approximate temperature of about 10 to 70 °C, preferably between 10 and 50 °C. 
Postupak iz patentnog zahtjeva 7 ili 8, pri čemu se rastvaranje kolesterola, ili njegovih derivata, u CF izvodi u reaktoru pod odgovarajućim pritiskom od 1 do 30 MPa i približnoj temperaturi od oko 10 do 70 *C, preporučljivo između 10 150 *C. 10.
stands for hydrogen atom or for straight or branched C1-4 alkyl group, or C3-6 cycloalkyl group, or a phenyl- or thienyl-, or furyl group, optionally substituted with one or more, identical or different, straight or branched C1-4 alkyl group, straight or branched C1-4 alkoxy group, or halogen atom, or or 6-membered heterocyclic ring containing one or two or three nitrogen atoms, or a 5-membered heterocyclic ring containing one nitrogen atom and one oxygen atom, or one nitrogen atom and one sulphur atom, optionally substituted with one or more, identical or different, straight or branched C1-4 alkyl group, straight or branched C1-4 alkoxy group, or halogen atom; 
predstavlja atom vodika ili nerazgranatu ili razgranatu C1-4 alkilnu skupinu ili C3-6 cikloalkilnu skupinu, ili fenilnu ili tienilnu ili furilnu skupinu, izborno supstituiranu s jednom ili više, istovjetnih ili različitih, nerazgranatih ili razgranatih C1-4 alkilnih skupina, nerazgranatih ili razgranatih C1-4 alkoksi skupina ili atoma halogena, ili ili 6-eročlani heterociklički prsten, koji sadrži jedan ili dva ili tri atoma dušika, ili 5-eročlani heterociklički prsten, koji sadrži jedan atom dušika i jedan atom kisika, ili jedan atom dušika i jedan atom sumpora, izborno supstituiran s jednom ili više, istovjetnih ili različitih, nerazgranatih ili razgranatih C1-4 alkilnih skupina, nerazgranatih ili razgranatih C1-4 alkoksi skupina ili atoma halogena;
The antibody-drug conjugate according to claim 1, wherein the anti-HER2 antibody comprises a heavy chain and a light chain selected from the group: 
Antitijelo-lijek konjugat u skladu sa patentnim zahtjevom 2, gdje je segment strukture lijek-veznik jedna lijek-veznik struktura odabrana od sljedeće grupe:
determining with the processor mechanism evidence of at least a third user mark in the detected third user marking cell based at least in part upon a degree of brightness similarity between: (a) at least a portion of the electronic image surrounding the at least one third indicium bounding the third user marking cell; and (b) at least a portion of the electronic image included inside the at least one third indicium bounding the third user marking cell. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što dodatno uključuje: određivanje procesorskim mehanizmom dokaza o u najmanju ruku trećoj korisničkoj oznaci u detektiranoj trećoj ćeliji za korisničku oznaku na temelju u najmanju ruku dijelom stupnja sličnosti svjetline između: (a) u najmanju ruku dijela elektronske slike koji okružuje bilješku koja omeđuje treću ćeliju za korisničku oznaku; 1 (b) u najmanju ruku dijela elektronske slike koji se nalazi unutar bilješke koja omeđuje treću ćeliju za korisničku oznaku.
A suitable protecting group Pg can be chosen depending on the type of the functional group, and a method described in the literature may be applied. 
Pogodnu zaštitnu skupinu Pg može se birati ovisno o tipu funkcionalne skupine, a može se primijeniti postupak opisan u literaturi.
at least one co-catalyst selected from organic compounds of an element M' different from carbon, said element M' being selected from elements belonging to groups 2, 12, 13 or 14, of the Periodic Table of Elements, preferably from: boron, aluminium, zinc, magnesium, gallium, tin, even more preferably aluminium, boron. 
(b) najmanje jedan kokatalizator izabran od organskih spojeva elementa M'* različitog od ugljika, pri čemu je navedeni element M' izabran od elemenata koji pripadaju grupama 2, 12, 13 ili 14, periodnog sustava elemenata, poželjno od: bora, aluminija, cinka, magnezija, galija, kositra, čak poželjnije aluminija, bora.
Final weight 572 mg. 
Konačna težina 572 mg.
A method according to claim 17, wherein the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 8 carbon atoms. 
Postupak prema patentnom zahtjevu 17, naznačen time da izraz alkil znači linearni ili razgranati ugljikovodični lanac koji sadrži 1 do 8 atoma ugljika.
This SDS removal, which is key to the formation of microaggregates, is the last step in the purification process of IL-2, prior to formulation. 
Ovo odstranjivanje SDS, koje je ključ za oblikovanje mikroagregata, je posljednji stupanj u procesu pročišćavanja IL-2 prije formuliranja.
trehalose; in combination with a proteolytic enzyme of bacterial origin and a proteolytic enzyme of fungal origin. A microencapsulated bacterial consortium, according to claim 1, wherein the encapsulating agents are selected from the group consisting of isolated protein from milk serum with 90% protein, maltodextrin with a dextrose equivalent of 10, arabic gum, mesquite gum, sodium alginate, pectin, soy isolated protein, casein and combinations thereof. 
Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 1, pri čemu su tri soja bakterija mliječne kiseline Lactobacillus plantarum ATCC 8014, Lactobacillus sanfranciscensis ATCC 27652 i Lactobacillus brevis ATCC Mikroenkapsulirani bakterijski konzorcij, prema zahtjevu 1, pri čemu su agensi za enkapsulaciju izabrani iz skupine koja sadrži izolirani protein iz mliječnog seruma s 90 % proteina, maltodekstrin s ekvivalentom dekstroze od 10, gumu arabiku, mesquite gumu, natrijev alginat, pektin, izolirani protein soje, kazein i njihove kombinacije.
the polypeptide comprises an amino acid change from SEQ ID NO: 67 residues 1-378 at one or more residues selected from the group consisting of amino acid residues 73, 102, 103, 104, 130, 165, 168, 169, 172, and 179. 
Polipeptid iz bilo kojeg od patentnih zahtjeva 1-8, gdje polipeptid sadrži aminokiselinsku sekvencu u skladu sa bilo kojim od SEK ID BR:2-16, 19, 21, 23-32 ostaci 1-567, i SEK ID BR:50, 53, 55 i 57-66 ostaci 1-378.
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to claim 1 or 2, wherein optionally said antigen-presenting cell comprises an expression vector expressing said peptide according to claim 1 or 2. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limoficta (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2,pri čemu opcionalno stanica koja prezentira antigen sadrži vektor ekspresije koji eksprimira navedeni peptid u skladu sa zahtjevom 1 ili 2.
Detection system as claimed in claim 18 or 19, characterized by a device connected controllably to the transmitting and receiving device for making at least one picture record of the passing vehicle. 
Sustav detekcije prema zahtjevu 10 ili 11, naznačen time što je uređaj za odašiljanje i primanje (4) prilagođen za prijenos barem jednog radarskog snopa (5) pod oštrim kutom prema smjeru vožnje prolazećeg vozila (V).
The blood brain barrier shuttle of claim 6, wherein the brain target is selected from the group consisting of B-secretase 1, AB, epidermal growth factor, epidermal growth factor receptor 2, Tau, phosphorylated Tau, apolipoprotein E4, alpha synuclein, oligomeric fragments of alpha synuclein, CD20, huntingtin, prion protein, leucine rich repeat kinase 2, parkin, presenilin 2, gamma secretase, death receptor 6, amyloid precursor protein, p75 neurotrophin receptor and caspase 6. 
No. 14, 15 ili 16 te time, da je entitet moždanog efektora odabran iz skupine koja se sastoji od lijekova za neurološke poremećaje, neurotrofnih faktora 1 protutijela usmjerenih na moždani cilj odabranih iz skupine koja se sastoji od B-sekretaze 1, Af, epidermalnog faktora Tasta, receptora 2 epidermalnog faktora rasta, Tau, fosforiliranog Tau, apolipoproteina E4, alfa sinukleina, oligomernih fragmenata alfa sinukleina, CD20, huntingtina, prionskog proteina, kinaze 2 bogate ponavljajućim leukinom, parkina, presenilina 2, gama sekretaze, receptora smrti 6, proteina amiloidnog prekursora, receptora neurotrofina p75 te kaspaze 6.
The remainder of the cells were swollen with 0.075 M KCl, washed with three consecutive changes of fixative (methanol:glacial acetic acid, 3:1 v/v), capped and stored overnight or longer at approximately 2-8° C. To prepare slides, the cells were collected by centrifugation and resuspended in fresh fixative. 
Preostali dio stanica je nabubrio sa 0.075 M KCI, ispran sa tri uzastopne promjene fiksativa (metanol:glacijalna octena kiselina, 3:1 vol./vol.), zatvoren i čuvan preko noći ili duže na približno 2-8*C. Za pripremu pločica, stanice su sakupljene centrifugiranjem i reasuspendirane u svježem fiksativu.
Mouse Atherosclerosis Model 
Model ateroskleroze miša
The method in accordance with claim 1, wherein one of the alignment electrodes is in direct contact with the layer, while the electric field is applied. 
Postupak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što je najmanje jedna od poravnavajućih elektroda u izravnom kontaktu sa slojem.
The antibody or antigen-binding fragment thereof as claimed in any one of claims 1-8, wherein the light chain has an amino acid sequence SEQ ID NO: 202. 
Protutijelo ili njegov fragment koji se veže na antigen prema jednom od zahtjeva 1 do 8, naznačen(o) time, da slabi lanac ima jednu amino kiselinsku sekvencu od SEQ ID NO: 36.
The pharmaceutical composition of claim 1, wherein the nucleotide sequence of the sense strand comprises GUAACCAAGAGUAUUCCAUNN (SEQ ID NO:449). 
sensni lanac sadrži SEQ ID NO:449 i antisensni lanac sadrži SEQ ID NO:450;
at least one sixth component (114) of inverted U-shape consisting of two vertical portions with an interposed horizontal portion intended to be transverse to the pallet plinths (18). 
najmanje jednu šestu komponentu (114) u obliku izokrenutog slova U koja se sastoji od dva okomita dijela s umetnutim vodoravnim dijelom koji bi trebao biti poprečan u odnosu na podnožja palete (18).
amino acids 22-509 of SEQ ID NO: 13, or a mutant or variant that comprises up to 5 amino acid substitutions as compared to the corresponding g3p portion of SEQ ID NO: 13; 
aminokiseline 22-509 SEK ID BR: 13, ili mutanta ili varijantu koja sadrži do 5 aminokiselinskih supstitucija u usporedbi s odgovarajućim dijelom g3p SEK ID BR: 13;
The boom mountable robotic arm of claim 1 further including an interruptible conductor having first and second ends and a plurality of electrically insulated support posts supporting said interruptible conductor away from said rigid member, wherein a rotatable electrically insulated support post of said at least one electrically insulated support post is rotatable relative to said upper beam assembly. 
Robotska ruka koja se može montirati na krak dizalice prema zahtjevu 1, naznačena time, da nadalje obuhvaća električni vodič koji se može prekidati, koji ima prvi i drugi kraj 1 veći broj električno izoliranih podupirača koji drže navedeni vodič koji se može prekidati, dalje od navedenog krutog elementa, pri čemu električno izolirani podupirač koji može rotirati, od navedenih barem jednog električno izoliranog podupirača, može rotirati u odnosu na navedeni gornji gredni sklop.
Total weight (film coated tablets) 
Ukupna masa (tablete presvučene filmom)
A compound of the general formula I: 
Spoj opće formule 1:
The present invention refers to a pharmaceutical composition for parenteral administration as vaccine comprising a monoclonal antibody and as adjuvant an aluminium derivative . 
Farmaceutska smjesa za parenteralnu primjenu kao cjepivo, naznačena time, što sadrži monoklonsko antitijelo i, kao adjuvans, derivat aluminija u koncentraciji od 2.4 do 5.2 mg/ml iona aluminija, u kojoj: -
The method of claim 1 wherein the gettering system comprises one or more of a Titanium deposition system and a Lithium deposition system that coat the plasma facing surfaces of the confine chamber and the first and second divertors. 
Postupak prema zahtjevu 1, 4 do 5 i 7, naznačen time, da getter-sustav obuhvaća jedan ili više sustava deponiranja titana (810) i sustava deponiranja litija (820), koji oblažu površine okrenute prema plazmi od priključne komore i od prvog i drugog preusmjerivača.
The kit of claim 16, wherein the reagent buffer comprises dNTPs at a concentration of from 1-10mM, one or more salts at a concentration of from 2-20mM, Tris pH8.8 at a concentration of from 10- 100mM, Trahalose at a concentration of from 10-100mM, BST polymerase at an amount of from 1U-12U and 0.01%-1% 1,2 propanediol. 
Komplet u skladu s patentnim zahtjevom 16, naznačen time što reagentni pufer sadrži dNTP u koncentraciji od 1-10 mM, jednu ili više soli u koncentraciji od 2-20 mM, Tris pH 8,8 u koncentraciji od 10-100 mM, trehaloza u koncentraciji od 10-100 mM, BST-polimerazu u količini od 1 U-12 U i 0,01%-1% 1,2-propandiola.
An afucosylated anti-CD20 antibody with an amount of fucose of 60 % or less of the total amount of oligosaccharides (sugars) at Asn297, for use in the treatment of cancer in combination with bendamustine, characterized in that said cancer is a CD20 expressing cancer and in that said antibody comprises an amino acid sequence of the variable region of the heavy chain (VH) of SEQ ID NO: 7, and an amino acid sequences of the variable region of the light chain (VL) of SEQ ID NO: 20. 
Afukozilirano protutijelo anti-CD20 s količinom fukoze od 60% 1li manje od ukupne količine oligosaharida (šećera) na Asn297, koje se upotrebljava u liječenju raka u kombinaciji s bendamustinom, naznačeno time, da spomenuti rak je rak koji izražava CD20, te time, da navedeno protutijelo obuhvaća aminokiselinsku sekvencu varijabilnog područja jakog lanca (VH) od SEQ ID NO:7, i aminokiselinsku sekvencu varijabilnog područja slabog lanca (VL) od SEQ ID NO:20.
The method of E 6, wherein the duration of the second treatment period is at least one year. 
1L-17 antagonist za uporabu u skladu sa zahtjevom 6, naznačen time, da je trajanje drugog razdoblja liječenja barem jedna godina.
Process according to any one of paragraphs 29 to 34, wherein the formation of the pharmaceutically acceptable salt is carried out in the presence of at least one organic solvent. Process according to paragraph 35, wherein the at least one organic solvent is used in an amount of 0.0001 to 2 vol%, particularly 0.01 to 1 vol%, more preferably from 0.1 to 0.7 vol%, based on the total volume of the reaction mixture. 
Postupak prema zahtjevu 12 ili 13, naznačen time, da se tvorba farmaceutski prihvatljive soli provodi u prisutnosti barem jednog organskog otapala, pri čemu se to barem jedno organsko otapalo poželjno upotrebljava u količini od 0,0001 do 2 volumenskih %, posebno od 0,01 do 1 volumenskog %, još bolje od 0,1 do 0,7 volumenskih %, na temelju ukupnog volumena reakcijske mješavine.
sensing physical conditions inside of the cylindrical body; 
očitavanje fizikalnih uvjeta temperature i vlage unutar cilindričnog tijela (110);
A method for preparing a conjugate comprising a cell-binding agent (CBA) conjugated to a cytotoxic compound with a linking group, the method comprising reacting a modified cytotoxic compound with a modified CBA at a pH of about 4 to about 9, wherein: 
Postupak pripreme konjugata koji sadrži agens za vezanje stanice (CBA) koji je konjugiran na citotoksični spoj s vezujućom skupinom, postupak sadrži reagiranje modificiranog citotoksičnog spoja s modificiranim CBA na pH od oko 4 do oko 8, naznačen time što:
and R2 represent, independently from one another, hydrogen, fluoro or chloro; with magnesium, and the obtained product is reacted with a compound of formula (III) 
R! i R*, međusobno neovisno, predstavljaju vodik, fluor ili klor; najprije reagira s magnezijem, a dobiveni produkt reagira sa spojem formule (III)
The compound according to claim 18, or the pharmaceutically acceptable salt thereof or the solvate thereof, wherein R8a is hydrogen, carbocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, heterocyclic group optionally substituted by substituent group C, or heterocycle lower alkyl optionally substituted by substituent group C (wherein substituent group C is same as that of claim 1). 
Spoj prema zahtjevu 18, ili njegova farmaceutski prihvatljiva sol, ili njegov solvat, naznačen time, da R* je vodik, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, ili heterociklil-niži alkil prema potrebi supstituiran sa supstituentskom skupinom €, (gdje supstituentska skupina C ima isto značenje kao što je navedeno u zahtjevu 1).
In still another specific embodiment, the VL CDR1 comprises, consists essentially of or consists of the amino acid sequence set forth in SEQ ID NO:7; the VL CDR2 comprises, consists essentially of or consists of the amino acid sequence set forth in SEQ ID NO:8; the VL CDR3 comprises, consists essentially of or consists of the amino acid sequence set forth in SEQ ID NO:9; the VH CDR1 comprises, consists essentially of or consists of the amino acid sequence set forth in SEQ ID NO:10; the VH CDR2 comprises, consists essentially of or consists of the amino acid sequence set forth in SEQ ID NO:11; and the VH CDR3 comprises, consists essentially of or consists of the amino acid sequence set forth in SEQ ID NO:12. 
Protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što VL CDR1 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:7; VL CDR2 sadrži ili ga čim aminokiselinski slijed iznijet u SEQ ID NO:8; VL CDR3 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:9; Vag CDRI sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO:10; Vg CDR2 sadrži ili ga čini aminokiselinski slijed iznijetu SEQ ID NO:11; 1 Va CDR3 sadrži ili ga čini aminokiselinski slijed iznijet u SEQ ID NO: 12.
It was concentrated to dryness, eliminating the solvent at reduced pressure. 
Koncentrira se do suhog i otapalo se odstrani pod smanjenim tlakom.
A pharmaceutical suspension as in claim 11 wherein the borate is boric acid. 
Farmaceutska suspenzija prema zahtjevu 10, naznačena time, da borat je borna kiselina.
The isolated nucleic acid of claim 20, wherein the variant AAV capsid protein, when present in an AAV virion, provides for increased infectivity of a photoreceptor cell by the AAV virion compared to the infectivity of the photoreceptor cell by an AAV virion comprising the corresponding parental AAV capsid protein. 
Izolirana nukleinska kiselina naznačena time što sadrži nukleotidnu sekvencu koja kodira varijantu kapsidnog proteina adeno-povezanog virusa (AAV), pri čemu je varijanta AAV kapsidnog proteina definirana kao u bilo kojem od zahtjeva 7 do 12.
The immunogenic composition of claim 37 wherein the additional antigens are antigens derived from a bacterium selected from the group consisting of S.pneumoniae, H.influenzae, N.meningitidis, E.coli, M.cattarhalis, tetanus, diphtheria, pertussis, S.epidermidis, enterococci, and S.aureus. 
Imunogeni pripravak u skladu s patentnim zahtjevom 37, naznačen time što su dodatni antigeni antigeni dobiveni iz bakterije koju se bira iz skupine koju čine S. pneumoniae, H. influenzae, N. meningitidis, E. coli, M. cattarhalis, tetanus, difterija, hripavac, S. epidermidis, enterokoki, te S. aureus.
320 µL (0.249 g, 2.41 mmol) of tert-butoxynitrite were added and stirred while covered and under cold conditions for 7 hours. 
Doda se 320 uL (0,249 g, 2,41 mmola) terc-butoksinitrita i miješa se 7 sati pokriveno i pod hladnim uvjetima.